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encouraged to consider this tool in constructing future economic
models.
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OBJECTIVE: Cost utility analysis (CUA) ﬁrst entered the 
literature in the 1970s and is now considered the standard for
examining the cost-effectiveness of health related interventions.
This study considers CUA as a methodological innovation and
traces its diffusion through the medically related literature for
twenty-ﬁve years. METHODS: We used the bibliography 
compiled at the Harvard School of Public Health
(http://www.hsph.harvard.edu/cearegistry/). All articles are orig-
inal CUAs indexed in MEDLINE and other electronic databases
from 1976 to 2001. For each article, we identiﬁed clinical area,
journal title and type (methods, general medicine, medical spe-
cialty, and other specialty). Medical specialty refers to those ﬁelds
considered subspecialties of medicine, such as cardiology and
gastroenterology, while other specialties include ﬁelds such as
radiology, surgery, nursing and pharmacology. We examined dis-
semination patterns of CUAs, and whether we could trace their
spread through the literature over time. RESULTS: The number
of CUAs (n = 539) plotted against year of publication yielded an
S-shaped curve, matching the classic diffusion pattern seen for
other innovations. Moreover, CUAs have diffused over time from
general medical journals and methodological journals into a
wide variety of specialty journals, tracing the typical pattern of
dissemination and adoption seen for other innovations. In
summary, for journal types methods, general medicine, medical
specialty, and other specialty, respectively, distribution of pub-
lished CUAs changed from 29%, 57%, 14%, and 0% during
1976–1984 to 14%, 29%, 37%, and 20% during 1998–2001
with transitional values in intervening time periods. CONCLU-
SIONS: The spread of CUAs through the literature follows pat-
terns commonly seen in the diffusion of innovations. It is
important to note that diffusion does not equal implementation.
Further study is required to determine whether the diffusion of
CUA has been accompanied by increasing use for decision
making in clinical practice or health policy.
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OBJECTIVES: Health care costs are rarely directly observed for
clinical trial subjects. What can be observed is medical resource
use. Designing a resource costing strategy involves determining
the degree of detailed resource data to collect and identifying unit
prices for those speciﬁc resources. A higher level of detail can
create a more speciﬁc estimate of costs, but this strategy increases
investigator burden. Our objective is to lay out the conceptual
framework of resource costing, draw implications, and provide
recommendations for weighing the tradeoffs of the design deci-
sions of resource costing. METHODS: For simplicity, assume
that medical costs are composed of two types of resources, X
and Y. Unit prices for resources X and Y are denoted px and py.
Now consider a bundled resource unit, Z where Z = X + Y. The
unit price for Z is pz = px + w*py where w = proportion of X in
price population. From this notation, we determine differences
in incremental costs estimates depending on whether these esti-
mates are based on resource use of bundled unit Z or its detailed
elements (i.e., X and Y). RESULTS: The bundling strategy will
produce a different estimate of relative incremental costs
between treatment groups if the proportions of each element of
the bundled resource item are not equivalent between treatment
groups. Absolute incremental costs will differ if the mix of
resources in the sample is different than the mix of resources in
the population from which the price is estimated. CONCLU-
SIONS: Bundling to reduce the burden of very detailed resource
use data and price weights is justiﬁed if the resources are bundled
into resource units that are not composed of items that are used
more intensely in one treatment group. Price adjustments should
be considered if the relative resource intensity is different
between the price population and the trial population.
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OBJECTIVES: Researchers routinely estimate the ratio of the
cost to the effect (C/E) for the comparison of cost-effectiveness
among treatment groups. There are, however, several limitations
in applying C/E ratios in practice, including conceptual and sta-
tistical difﬁculties of ratio variables as well as issues concerning
the control of confounding biases. Treatment and comparison
groups, in observational study, are rarely comparable. Propen-
sity score methods (PSMs) as well as regression methods may be
applied to overcome confounding bias. To our knowledge, no
published study has compared the use of PSM to regression
methods for the evaluation of cost-effectiveness. The objective of
this study, therefore, is to report on the C/E ratio test, the PSM,
and a regression-based statistical model. METHODS: Simulated
data were used to compare results derived from the C/E ratio
test, the PSM, and a regression-based statistical model.
RESULTS: Results from the statistical and PSM models revealed
that cost-effectiveness evaluations can be confounded by
patients’ characteristics. CONCLUSIONS: Compared with the
crude estimate, PSM and regression-based methods can be 
used with observational data to estimate treatment group cost-
effectiveness differences controlling for observed heterogeneity.
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OBJECTIVES: Until now, the input to CE simulations was pri-
marily the probability of events and costs associated with them.
The probabilities are based on raw frequency data available or
logistic regression models. The goal of this research improve sim-
ulations by incorporating Cox proportional hazards (CPH)
analyses into these models to increase their validity and useful-
ness to policy makers. METHODS: A CPH analysis estimates
the coefﬁcients of a linear combination of predictors. Raising this
to the “e” power provides the hazard ratio comparing a group
of subjects deﬁned by a speciﬁc vector of predictors to an
“average” referent group. Once a Cox model is estimated, we
deﬁne a hazard ISOBAR as the set of values that make the linear
combination of predictors equal to a constant “c”. “C” can be
varied freely. This “c” can be used as the criteria for interven-
